We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Eli Lilly and Co | NYSE:LLY | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 30.53 | 4.15% | 765.50 | 766.99 | 736.00 | 738.04 | 3,395,720 | 23:41:06 |
From May 2019 to May 2024
The health-care sector fell as earnings came in generally weak. Eli Lilly posted a decline in quarterly profit despite higher drug sales as higher research-and-development costs and a currency devaluation in Venezuela took their toll. Sarepta Therapeutics plunged after an advisory panel to the Food and Drug Administration voted not to recommend approval of its drug for Duchenne muscular dystrophy, which had excited hopes among investors. (rob.curran@dowjones.com)
(END) Dow Jones Newswires
April 26, 2016 16:26 ET (20:26 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year Eli Lilly Chart |
1 Month Eli Lilly Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
